Cardinal Health vs McKesson
McKesson holds the stronger position because it moves more drug volume and posts a larger cash cushion than Cardinal Health.
Cardinal Health
Drug and medical supply wholesaler delivering to most US hospitals and pharmacies
McKesson
Drug wholesaler moving roughly a third of North America's prescription medicines
Dimension by dimension
| Dimension | Cardinal Health | McKesson |
|---|---|---|
| Staying power of the core product | Cardinal Health delivers to most U.S. hospitals and pharmacies, playing a similarly essential role in the drug supply chain. | McKesson distributes roughly a third of all U.S. pharmaceutical products, a role hospitals and pharmacies depend on daily. |
| Exposure to AI | Cardinal Health's distribution work is just as unlikely to be absorbed by AI. | McKesson's physical drug distribution is unlikely to be replaced by AI software. |
| How easily a giant copies them | Cardinal Health's nationwide delivery infrastructure is similarly blocked from easy copying. | McKesson's scale and existing distribution network make it hard for a new entrant to replicate. |
| Pressure from rivals | Cardinal Health faces lighter direct rival pressure than McKesson, with no reported customer losses either, assessed July 2026. | McKesson faces some competitive pressure from other national distributors, though it has not reported losing major customers, assessed July 2026. |
| Position strength score | Cardinal Health holds a slightly weaker overall market position than McKesson, given its smaller revenue scale. | McKesson holds a stronger overall market position than Cardinal Health, reflected in its larger revenue base and free cash flow generation. |
| Revenue scale and growth | Cardinal Health posted $222.6 billion in FY2025 revenue, with trailing twelve month revenue at $250.7 billion and Q3 FY2026 growth of 11% year over year. | McKesson posted $359.05 billion in FY2025 revenue and grew 12% year over year in FY2026. |
| Financial footing | No free cash flow figure is available for Cardinal Health in the given data. | McKesson generated $5.4 billion in free cash flow in FY2026, showing a solid cash buffer. |
Questions people ask
- McKesson vs Cardinal Health which is bigger
- McKesson is larger by revenue, posting $359.05 billion in FY2025 compared to Cardinal Health's $222.6 billion. Cardinal Health's trailing twelve month revenue of $250.7 billion still trails McKesson's scale.
- Is McKesson or Cardinal Health more at risk from AI
- Neither company faces much AI risk since both run physical drug distribution networks that AI is unlikely to absorb. McKesson and Cardinal Health both carry an unlikely rating on this measure.
- Can a big tech company copy McKesson or Cardinal Health
- Both companies are rated as blocked from easy copying by a giant, given their entrenched distribution networks. McKesson and Cardinal Health each hold a scale advantage that would be hard for a new entrant to match.
- Which company has stronger financials, McKesson or Cardinal Health
- McKesson reports $5.4 billion in free cash flow for FY2026 alongside 12% revenue growth, giving a clearer financial picture. Cardinal Health shows strong revenue growth of 11% in its most recent quarter, but no free cash flow figure is available for comparison.
Other comparisons with these companies